CLL Society’s 2026 Clinical Scholar Award – Dr. Kerry Rogers
August 3, 2026
CLL Society awarded Dr. Matthews Davids a research grant for his project Optimizing Glofitamab Combination Therapy in Richter’s Transformation.
CLL Society awarded Dr. Matthews Davids a research grant for his project Optimizing Glofitamab Combination Therapy in Richter’s Transformation.
In the real world, patients with CLL treated with liso-cel (CAR-T) have response rates that are just as good or even higher than those seen in clinical trials.
As anyone who has followed trends in chronic lymphocytic leukemia (CLL) knows, the treatment options for patients with this disease have evolved greatly over the past two decades.
CLL patients now have multiple excellent choices between limited-duration and continuous targeted therapies that all can offer durable disease control. Choosing between them depends on multiple factors.
Preclinical research shows that rocbrutinib inhibits BTK and B-cell receptor pathway signaling even in the presence of BTK mutations commonly seen in CLL.
BTK degrader BGB-16673 produced high response rates and was well tolerated in a heavily treated, high-risk group of patients with CLL / SLL
In the real-world, patients with CLL treated with liso-cel have response rates that are just as good or even higher than those seen in clinical trials.
Rocbrutinib appears to be effective in CLL patients with prior exposure to covalent and noncovalent BTKi, and it is generally well-tolerated.
Terry Evans, Director of CLL Society Support & Education Network, shares his CLL journey, experience with clinical trials, and his later-in-life love of golf.